



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete If Known

Application Number	09/808,832
Filing Date	March 15, 2001
First Named Inventor	Copeland et al
Group Art Unit	16534
Examiner Name	J. Russell - Russell
Attorney Docket Number	PH-7134

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
JR	AA	5,962,216		Trouet et al	10/5/1999	435/4
JR	AB	4,703,107		Monsigny et al	10/27/1987	530/330
JR	AC	6,342,480		Trouet et al	1/29/2002	514/18

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T e
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
JR		WO	9600503		Merck & Co. Inc.	1/11/1996		
JR		WO	9605863		La Region Wallonne	2/29/1996	See AA & AC	
JR		WO	9712624		Merck & Co. Inc.	4/10/1997		
JR		WO	9714416		Merck & Co. Inc.	4/24/1997		
JR		WO	9748725		Peptech Limited	12/24/1997		
JR		WO	9810651		Merck & Co. Inc.	3/19/1998		
JR		WO	9810795		Burnham Inst.	3/19/1998		
JR		WO	9816240		Liposome Co. Inc.	4/23/1998		
JR		WO	9818493		Merck & Co. Inc.	5/7/1998		
JR		WO	9846250		The Regents of the Univ. of CA	10/22/1998		
JR		WO	9902175		Merck & Co. Inc.	1/21/1999		
JR		WO	0033888		Coulter Pharmaceutical, Inc.	6/15/2000		
JR		WO	0059930		Merck & Co. Inc.	10/12/2000		
JR		WO	0064486	✓	Veritas Medical Techn., Inc.	11/2/2000		
JR		WO	0071571		Boehringer Ingelheim	11/30/2000		
JR		EP	126685		Centre National de la Recherche Scientifique	11/28/1984	See AB	
JR		EP	359347		Neorx Corporation	3/21/1990		
JR		UK	2131813	✓	Monsanto Co.	6/27/1984		
Examiner Signature		Jeffrey E. Russell			Date Considered	December 3, 2002		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

RECEIVED

NOV 19 2002



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 Of 3

Complete if Known

Application Number	09/808,832
Filing Date	March 15, 2001
First Named Inventor	Copeland et al
Group Art Unit	16524
Examiner Name	J. Russell Russell
Attorney Docket Number	PH-7134

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
JRL	1	TIMAR et al, "The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site" Cancer Chemotherapy Pharmacology, vol. 41, no. 4, 1998, 292-298	
JRL		MASQUELIER et al, "Amino Acid and Dipeptide Derivatives of Daunorubicin. 1. Synthesis, Physicochemical Properties, and Lysosomal Digestion", Journal of Medicinal Chemistry, American Chemical Society, vol. 23, no. 11, 1980, 1166-1170.	
JRL		DENMEADE et al, "Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen", Cancer Research, American Assoc. for Cancer Research, vol. 58, June 15, 1998, 2537-2540	
JRL		SAFAVY et al, "Paclitaxel Derivatives for Targeted Therapy of Cancer: Toward the Development of Smart Taxanes" Journal of Medicinal Chemistry, Am. Chem. Soc., vol. 42, 1999, 4919-4924	
JRL		MCGEEHAN et al, "Characterization of the Peptide Substrate Specificities of Interstitial Collagenase and 92-KDA Gelatinase Implications of Substrate Optimization" Journal of Biological Chem., vol. 269, no 52, Dec. 30, 1994, 32814-32820	
JRL		AIMES et al, Matrix Metalloproteinase-2 Is an Interstitial Collagenase, Journal of Biological Chemistry, vol. 270, No. 11, March 17, 1995, 5872-5876, 1995	
JRL		KURSCHAT et al, Tissue Inhibitor of Matrix Metalloproteinase-2 Regulates Matrix Metalloproteinase-2 Activation by Modulation of Membrane-type 1 Matrix Metalloproteinase Activity in High and Low Invasive Melanoma Cell Lines, Journal of Biological Chemistry, vol. 274, No. 30, 21056-21062, 1999	
JRL		GARBISA et al, Correlation of Serum Metalloproteinase Levels with Lung Cancer Metastasis and Response to Therapy, Cancer Research, 52, 4548-4549, 1992	
JRL		BOVEN et al, Doxorubicin Compared with Related Compounds in a Nude Mouse Model for Human Ovarian Cancer, Eur. J. Cancer, Vol. 26, no. 9, 983-986, 1990	
JRL		KNAUPER et al, Biochemical Characterization of Human Collagenase-3, Biological Chemistry, Vol. 271, No. 3, 1544-1550, 1996	
JRL		BROOKS et al, Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin $\alpha v \beta 3$, Cell, Vol. 85, 683-693, 1996	
JRL		MOSES et al, Increased Incidence of Matrix Metalloproteinases in Urine of Cancer Patients, Cancer Research, 58, 1395-1399, 1998	
JRL		CANAL et al, Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities, Clin. Pharmacol. Ther., volume 51, number 3, 249-259, 1992	
JRL		BOVEN et al, The anti-tumour effects of the prodrugs N-L-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts, Br. J. Cancer, 66, 1044-1047, 1992	
Examiner Signature	Jeffrey E. Russell		Date Considered
			December 3, 2002

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Unique citation designation number. ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *** Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

+ RECEIVED
NOV 19 2002
PCT CENTER 1600/2900



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
Substitute for form 1449A/PTO		Application Number	09/808,832
		Filing Date	March 15, 2001
		First Named Inventor	Copeland et al
		Group Art Unit	16534
		Examiner Name	J. Russell-Russell
		Attorney Docket Number	PH-7134
Sheet	3	Of	3
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
JR		MCDONNELL et al, Role of matrix metalloproteinases in invasion and metastasis: biology, diagnosis and inhibitors, Cytotechnology, 12, 367-384, 1993	
JR		BRUMMER et al, Matrix-metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study, Virchows Arch, 435, 566-573, 1999	
JR		MACDOUGALL et al, Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis, Cancer and Metastasis Reviews, 14, 351-362, 1995	
JR		DE JONG et al, Plasma Pharmacokinetics and Pharmacodynamics of a New Prodrug N-I-Leucyldoxorubicin and Its Metabolites in a Phase I Clinical Trial, Journal of Clinical Oncology, vol. 10, no. 12, 1897-1906, 1992	
JR		DE GROOT et al, Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin, J. Med. Chem., 42, 5277-5283, 1999	
JR		SAFAVY et al, Paclitaxel Derivatives for Targeted Therapy of Cancer: Toward the Development of Smart Taxanes, J. Med. Chem., 42, 4919-4924, 1999	
JR		NAGASE et al, Human Matrix Metalloproteinase Specificity Studies Using Collagen Sequence-Based Synthetic Peptides, Biopolymers, vol. 40, 399-416, 1996	
JR		WHITTAKER et al, Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors, Chem. Rev. 99, 2735-2776, 1999	
Examiner Signature	Jeffrey E. Russell		Date Considered December 3, 2002

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231